Kuchimanchi M, Monine M, Kandadi Muralidharan K, Woodward C, Penner N. Phase II Dose Selection for Alpha Synuclein-Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain. CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):515-522. Epub 2020 Aug 19 PubMed.
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.